(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 351.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Mesoblast's revenue in 2025 is $5,670,000.On average, 2 Wall Street analysts forecast MESO's revenue for 2026 to be $75,859,654,539, with the lowest MESO revenue forecast at $72,200,643,477, and the highest MESO revenue forecast at $79,518,665,601.
In 2027, MESO is forecast to generate $337,666,217,697 in revenue, with the lowest revenue forecast at $337,666,217,697 and the highest revenue forecast at $337,666,217,697.